Oppenheimer & Co. Inc. cut its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 0.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 349,696 shares of the biopharmaceutical company’s stock after selling 1,995 shares during the period. Oppenheimer & Co. Inc.’s holdings in Bristol-Myers Squibb were worth $19,017,000 as of its most recent filing with the SEC.

Several other large investors also recently added to or reduced their stakes in the stock. American National Bank raised its stake in Bristol-Myers Squibb by 36.0% in the first quarter. American National Bank now owns 1,919 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 508 shares in the last quarter. Welch Investments LLC raised its stake in Bristol-Myers Squibb by 3.9% in the first quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 79 shares in the last quarter. Crestwood Advisors Group LLC bought a new stake in Bristol-Myers Squibb during the first quarter valued at $116,000. Blue Chip Partners Inc. raised its stake in Bristol-Myers Squibb by 0.8% in the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 17 shares in the last quarter. Finally, State of Alaska Department of Revenue raised its stake in Bristol-Myers Squibb by 2.8% in the first quarter. State of Alaska Department of Revenue now owns 2,229 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 60 shares in the last quarter. Institutional investors own 69.79% of the company’s stock.

Bristol-Myers Squibb Company (BMY) traded down 0.3936% on Thursday, hitting $57.1741. The stock had a trading volume of 1,364,640 shares. The company’s 50 day moving average is $55.81 and its 200-day moving average is $54.58. Bristol-Myers Squibb Company has a 1-year low of $46.01 and a 1-year high of $61.30. The firm has a market capitalization of $93.76 billion, a price-to-earnings ratio of 20.8817 and a beta of 1.17.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The company had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. During the same quarter in the prior year, the business posted $0.69 EPS. The firm’s revenue was up 5.6% compared to the same quarter last year. On average, analysts forecast that Bristol-Myers Squibb Company will post $2.97 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, August 1st. Investors of record on Friday, July 7th were issued a $0.39 dividend. The ex-dividend date was Wednesday, July 5th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.72%. Bristol-Myers Squibb’s dividend payout ratio is presently 56.73%.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/08/10/oppenheimer-co-inc-has-19-02-million-position-in-bristol-myers-squibb-company-nysebmy.html.

A number of equities research analysts recently commented on the company. BidaskClub upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Saturday, June 10th. Deutsche Bank AG set a $55.00 price target on Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Monday, July 17th. BMO Capital Markets lowered Bristol-Myers Squibb from a “market perform” rating to an “underperform” rating and set a $47.00 price target on the stock. in a research report on Wednesday, May 3rd. Jefferies Group LLC restated a “buy” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Wednesday, July 12th. Finally, Vetr lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $63.81 price target on the stock. in a research report on Wednesday. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and twelve have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $62.67.

In other Bristol-Myers Squibb news, Director Theodore R. Samuels II bought 6,000 shares of the stock in a transaction that occurred on Wednesday, August 2nd. The shares were bought at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the acquisition, the director now directly owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.23% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.